• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices.

作者信息

Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M

机构信息

Division of Pharmacology, Osaka University of Pharmaceutical Sciences, Japan.

出版信息

Toxicol Lett. 1990 Jun;52(1):15-24. doi: 10.1016/0378-4274(90)90161-e.

DOI:10.1016/0378-4274(90)90161-e
PMID:2356567
Abstract

The addition of a new compound containing platinum, 254-S, an antineoplastic agent, to medium had no effect on p-aminohippurate (PAH) accumulation, gluconeogenesis, or potassium and ATP concentrations in rat kidney cortical slices at the concentrations tested, up to 10 mM. At 1 mM, cisplatin, used for comparison, significantly decreased all of these biochemical indices in the slices. Administration of 254-S at a low dose (10 mg/kg i.v.) to rats decreased the ability of the slices to accumulate PAH and to maintain the potassium concentration, without affecting levels of urea or creatinine in blood plasma. 254-S at a high dose (20 mg/kg i.v.) or cisplatin at 5 mg/kg (i.v.) also decreased these indices in the slices, and affected urea and creatinine in blood plasma. These results suggested that use of the renal slice technique gives data useful for the evaluation of the nephrotoxicity of 254-S, and that PAH accumulation and the potassium concentration in slices from rats treated with 254-S are indicators of nephrotoxic damage.

摘要

相似文献

1
Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices.
Toxicol Lett. 1990 Jun;52(1):15-24. doi: 10.1016/0378-4274(90)90161-e.
2
Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.顺铂、卡铂和反铂的肾毒性。一项体外比较研究。
Arch Toxicol. 1990;64(5):393-400. doi: 10.1007/BF01973462.
3
Amelioration of cisplatin toxicity in rat renal cortical slices by dithiothreitol in vitro.二硫苏糖醇对大鼠肾皮质切片顺铂毒性的体外改善作用。
Hum Exp Toxicol. 1994 Feb;13(2):89-93. doi: 10.1177/096032719401300205.
4
Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers.顺铂诱导大鼠肾皮质脂质过氧化及糖异生减少:抗氧化剂和自由基清除剂的不同作用
Toxicology. 1988 Oct;51(2-3):119-32. doi: 10.1016/0300-483x(88)90143-6.
5
Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.奥沙利铂致大鼠肾皮质切片肾脏病变的实验研究
Clin Exp Nephrol. 2004 Dec;8(4):310-5. doi: 10.1007/s10157-004-0304-0.
6
The effect of methylprednisolone on cisplatin-induced nephrotoxicity in rat renal cortical slices.甲基强的松龙对顺铂诱导的大鼠肾皮质切片肾毒性的影响。
Res Exp Med (Berl). 1995;195(4):231-5. doi: 10.1007/BF02576792.
7
Nonionic contrast media are less nephrotoxic than ionic contrast media to rat renal cortical slices.
Toxicol Lett. 2003 Jun 5;143(1):17-25. doi: 10.1016/s0378-4274(03)00091-2.
8
Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices.
Hum Exp Toxicol. 1996 Jan;15(1):59-63. doi: 10.1177/096032719601500111.
9
Comparative nephrotoxicity of tetraplatin and cisplatin in rats.
Nephron. 1993;64(2):289-95. doi: 10.1159/000187328.
10
Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.美罗培南和亚胺培南/西司他丁在大鼠和人肾皮质切片及微粒体中的肾毒性和过氧化潜力。
Int J Clin Pharmacol Ther. 1999 Oct;37(10):475-86.

引用本文的文献

1
FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma.FAN评分可预测转移性尿路上皮癌患者接受铂类一线化疗后的预后。
Sci Rep. 2025 Feb 7;15(1):4640. doi: 10.1038/s41598-025-86212-7.
2
Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis.东亚人群中奈达铂与顺铂为基础的化疗方案治疗晚期非小细胞肺癌的比较:一项荟萃分析。
Sci Rep. 2015 May 21;5:10516. doi: 10.1038/srep10516.
3
Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma.
奈达铂同步放化疗治疗IIA至IVA期宫颈癌患者
Mol Clin Oncol. 2013 Jan;1(1):165-170. doi: 10.3892/mco.2012.27. Epub 2012 Sep 25.
4
A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma.紫杉醇联合奈达铂一线治疗中国转移性食管鳞癌的 II 期临床研究。
World J Gastroenterol. 2013 Sep 21;19(35):5910-6. doi: 10.3748/wjg.v19.i35.5910.
5
[A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage
treatment in refractory or relapsed small cell lung cancer].伊立替康联合奈达铂与伊立替康联合顺铂作为难治性或复发性小细胞肺癌挽救治疗的疗效和毒性的回顾性研究
Zhongguo Fei Ai Za Zhi. 2013 Sep;16(9):470-5. doi: 10.3779/j.issn.1009-3419.2013.09.06.
6
Nedaplatin: a cisplatin derivative in cancer chemotherapy.奈达铂:癌症化疗中的顺铂衍生物。
Cancer Manag Res. 2013 May 8;5:67-76. doi: 10.2147/CMAR.S35785. Print 2013.
7
Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial.奈达铂/吉西他滨与卡铂/吉西他滨治疗晚期非小细胞肺癌的随机临床试验。
Chin J Cancer Res. 2012 Jun;24(2):97-102. doi: 10.1007/s11670-012-0097-8.
8
cis-Diammine(glycolato-κO,O)platinum(II).顺-二氨(乙二醇酸根-κO,O)铂(II)
Acta Crystallogr Sect E Struct Rep Online. 2009 Nov 28;65(Pt 12):m1687. doi: 10.1107/S1600536809049757.
9
Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.Ⅱ期研究:奈达铂和伊立替康联合胸部放疗治疗局部晚期非小细胞肺癌。
Br J Cancer. 2010 Oct 26;103(9):1325-30. doi: 10.1038/sj.bjc.6605875. Epub 2010 Oct 12.
10
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.前瞻性研究每日低剂量奈达铂和持续 5-氟尿嘧啶输注联合放疗治疗食管鳞状细胞癌。
BMC Cancer. 2009 Nov 22;9:408. doi: 10.1186/1471-2407-9-408.